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Abstract 
Extra-cellular vesicles (EVs) derived from human bone marrow mesenchymal stromal cells (MSCs) 
promote the regeneration of kidneys in different animal models of AKI in a manner comparable to 
the cells of origin. However, due to the heterogeneity observed in the EVs isolated from MSC, it is 
unclear which population is responsible for the pro-regenerative effects.  
We therefore evaluated the effect of various EV-populations separated by differential 
ultracentrifugation (10K population enriched with microvesicles and 100K population enriched with 
exosomes) on AKI recovery. Only the exosomal-enriched population induced an improvement of 
renal function and morphology, comparable with that of the total EV population. Interestingly, the 
100K EVs exerted a pro-proliferative effect on murine tubular cells, both in vitro and in vivo. 
Analysis of the molecular content from the different EV populations revealed a distinct profile. The 
100K population for instance was enriched in specific mRNAs (CCNB1, CDK8, CDC6) reported to 
influence cell cycle entry and progression; miRNAs involved in regulating proliferative/anti-
apoptotic pathways and growth factors (HGF and IGF-1) that could explain the effect of renal 
tubular cell proliferation. On the other hand, the EV population enriched in microvesicles (10K), 
was unable to induce renal regeneration and had a molecular profile with lower expression of pro-
proliferative molecules. In conclusion, the different molecular composition of exosome- and 
microvesicle-enriched populations may explain the regenerative effect of EVs observed in AKI. 
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Introduction 
Stem cells are important in the maintenance of tissue homeostasis and restoration after injury. One 
of the mechanisms by which they can influence the behaviour of injured cells is through secreting 
soluble factors and extracellular vesicles (EVs). In particular, EVs carry a broad range of bioactive 
molecules including proteins, nucleic acids (mRNA, miRNA, lncRNA, DNA) and lipids, which can 
act on different cell types triggering a pro-proliferative and or pro-regenerative program 
(angiogenesis, immune tolerance, etc) (1-5). For instance, mRNA and miRNA delivered by EVs 
released from endothelial progenitor cells (EPC) induces endothelial cell proliferation and 
revascularization of injured murine tissue (6, 8). Furthermore, they can also mediate a robust pro-
angiogenic program and wound healing effects in streptozotocin-induced diabetic rats through the 
activation of Erk1/2 signalling pathway (8). In a model of heart injury, exosomes derived from 
human cardiac progenitor cells inhibit apoptosis and increase cardiomyocytes and endothelial cell 
proliferation (9).  
Among the different stem cells extensively employed in research and clinical practice, 
mesenchymal stem cells (MSCs) are the most widely used (10). MSCs isolated from different adult 
tissues (bone marrow, adipose tissue, or neonatal umbilical cord) possess immunomodulatory 
characteristics and migrate to injured tissues secreting factors and EVs (11, 12). For instance, 
human umbilical cord derived MSC-EVs have been shown to reduce fibrosis and collagen 
deposition in a model of drug-induced liver injury (13). Moreover, in a model of hypoxia induced 
pulmonary hypertension, MSC-EVs mediated the reduction of inflammation and enhanced the 
recovery of injured lung tissue (14, 15).  
The regenerative potential of mesenchymal stem cells derived EVs (MSC-EVs) has also been 
investigated in different renal injury models. MSC-EVs improved survival in mice treated with 
cisplatin and reduced the incidence of chronic kidney disease (16). In glycerol-induced acute kidney 
injury (AKI), a single administration of MSC-EVs accelerated functional and histological recovery 
by delivery of selected miRNAs and mRNAs (17, 18). AKI and development chronic kidney 
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disease (CKD) were also prevented in an ischemia and reperfusion injury (IRI) model through the 
administration of a single dose of MSC-EVs (19). However, like other stem cells, MSCs also 
secrete various populations of EVs that shuttle a wide range of molecules which exhibit different 
effects on target cells (20). Currently, a lot of attention is being focussed on the characterization of 
stem cell EVs together with the cargo they carry (18, 21, 22). However, many “omic” studies are 
addressed only on the exosomal fraction of EVs. For instance, De Luca et al. characterized the 
miRNA and piRNA content of bone marrow MSC exosomes and demonstrated that the RNA 
content can modify the fate of umbilical cord blood derived CD34+ cells (23). Furthermore, protein 
and miRNA carried by MSC derived exosomes have also been shown to possess tumor regulatory 
capacity (24).  
In the present study, we evaluated the effect of MSC-derived exosomes and microvesicles on AKI 
recovery. For this purpose, we purified the 10K and 100K fractions of EVs by differential 
ultracentrifugation and correlated their in vivo and in vitro biological effects observed with their 
molecular composition. 
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Materials and methods 
Cell cultures 
Bone marrow MSCs were obtained by Lonza (Basel, Switzerland) and cultured and characterized as 
previously described (17). MSCs derived from 5 preparations were used up to the sixth passage of 
culture. All of the cell preparations used were positive for the typical MSC markers (CD105, CD29, 
CD73, CD44 and CD90) and had the ability to differentiate into adipogenic and osteogenic lineages 
(not shown).  
Murine tubular cells (mTECs) were obtained as previously described (17). The cells were 
maintained in DMEM (Euroclone) supplemented with 10% Fetal calf serum (FCS, Euroclone) and 
were positive for typical mTEC markers such as: cytokeratin, alkaline phosphatase and 
aminopeptidase A, and negative for endothelial (von Willebrand factor), hematopoietic (CD45) and 
glomerular (nephrin) markers (not shown). 
Isolation and characterization of different fractions of MSC-EVs 
EVs were obtained from supernatants of MSCs cultured overnight in RPMI deprived of FCS. The 
viability of MSCs at the time of EV collection was 99% as determined by trypan blue exclusion. 
After removal of cell debris and apoptotic bodies by centrifugation at 3,000g for 20 minutes, EVs 
were purified by different steps of ultracentrifugation: 
- 100KTOT-EVs were purified by 2-hour ultracentrifugation at 100,000g at 4°C (Beckman Coulter 
Optima L-90K, Fullerton, CA, UAS); 
- 10K-EVs were purified by 2-hour ultracentrifugation at 10,000g at 4°C; 
- 100K-EVs were purified by 2-hour ultracentrifugation at 100,000g at 4°C of supernatant deprived 
of 10K-EVs.  
EVs from the different fractions were used freshly or stored at -80° C after re-suspension in RPMI 
supplemented with 1% DMSO. Analysis of size distribution and enumeration of EVs were 
performed using NanoSight LM10 (NanoSight Ltd) equipped with a 405 nm laser and NTA 2.3 
software. Using a laser light source the particles in the sample are illuminated and the scattered light 
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is captured by the camera and displayed on the connected computer running Nanoparticle Tracking 
Analysis (NTA). Using NTA, the particles are automatically tracked and sized based on Brownian 
motion and the diffusion coefficient (Dt). Three videos of 30 seconds were recorded in order to 
perform the analyses. EVs were characterized by cytofluorimetric analysis using FITC, PE or APC 
conjugated antibodies against CD73, CD44, CD105 and CD29. Conjugated mouse non-immune 
isotypic IgG (Miltenyi Biotec,) were used as control. Briefly, EVs (1.5x108 particles) were 
incubated at 4°C for 15 min with the antibodies, then diluted 1:3 and acquired immediately as 
described previously (25). Samples were acquired using Guava easyCyte Flow Cytometer 
(Millipore) and analyzed with InCyte software.  
In selected experiments, the EV pellet obtained by differential ultracentrifugation was further 
purified using an iodixanol (Optiprep from Sigma) floating separation protocol. Briefly, the pellet 
was directly resuspended in 500 µl of 60% iodixanol mixed with 0.25M sucrose and transferred to 
an ultracentrifuge tube (Beckman Instruments). Various gradients of iodixanol: 30%, 15%, and 5% 
were than sequentially layered on top of the EV/60% iodixanol prep. A final volume of 10 ml was 
than obtained by adding saline solution on top of the 5% iodixanol fraction. The tubes were than 
ultra-centrifuged at 350,000g for 1 hour at 4°C without breaking in an Optima L-100K 
ultracentrifuge (Beckman Coulter) equipped with Type 90Ti rotor. The 15%, 30%, and 60% 
fractions were recovered, diluted with PBS, and ultracentrifuged again at 100,000g for 1 hour at 
4°C. The pellet obtained was resuspended in PBS with 1% DMSO and frozen or used for 
subsequent studies. NanoSight analyses revealed that vesicles recovered by floating were mainly 
detected in the 15% fraction (70% of EVs) and to a lower extent in the 30% fraction (30% of EVs). 
Furthermore, Western blot analysis showed that the exosomal marker CD63 was mainly detected in 
the 15% fraction (Figure 1A). 
RNA extraction and mRNA analysis 
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RNA was extracted from different EV populations using the All in one kit (Norgen) according to 
the manufacturer’s protocol. Human Cell Cycle RT² Profiler™ PCR Array (SABioscience-Qiagen) 
was performed to profile the expression of 84 genes related to cell cycle regulation. 
To confirm the mRNA expression of selected genes, cDNA was obtained using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). 5 ng of cDNA and 200 nM of each primer 
(Table 1) were added to 1X SYBR GREEN PCR Master Mix (Applied Biosystems) and run on a 
96-well StepOne quantitative Real Time PCR (qRT-PCR) System (Applied Biosystems). GAPDH 
was used as a housekeeping gene.  
Small RNA seq 
Small RNA libraries for micro-RNA sequencing were prepared using the TruSeq Small RNA 
Library Preparation Kit according to the manufacturer's protocol. The size of the library was 
checked by using a Fragment Analyzer instrument. Samples were sequenced on an Illumina 
HiScanSQ platform (Illumina). Sequencing reads were trimmed out of the low-quality bases and 
adapter clipped with Fastx Toolkit. Filtered sequences were mapped and quantified by using 
miRDeep2 software (26) on the most updated version of the human miRBase database (27). For 
downstream analysis, miRNAs with RPM < 100 in all the samples were filtered out. miRNAs with 
a Fold change of log2 (FC)≤ 1 and log2(FC) ≥ 1 were considered as up-regulated or down-regulated 
in the different populations, respectively. 
miRNA prediction and network analysis.  
Target prediction and biological process enrichment analysis was performed using the Funrich 
analysis tool (28). Only biological processes of selected genes showing a p value <0.05 were 
considered as significantly enriched. Network analysis to define the associated pathways of the 
100K and 10K miRNA-predictive genes, was conducted using the Funrich interaction plug-in (p 
value <0.01 in the enriched pathways). A filter of a minimum of 6 interactions among different 
nodes was applied.  
Protein expression analysis 
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Proteins were extracted from different EV populations by RIPA buffer (20 nM Tris-HCl, 150 nM 
NaCl, 1% deoxycholate, 0.1% SDS, 1% Triton X-100, pH 7.8) supplemented with a cocktail of 
protease and phosphatase inhibitors (Sigma-Aldrich). The protein content was quantified by BCA 
Protein Assay Kit (Pierce, Thermo Fisher Scientific). 30 µg of proteins were separated by 
electrophoresis using a 4% to 15% gradient sodium dodecyl sulfate–polyacrylamide gel. The 
proteins were transferred to a PVDF membrane by the iBlot™ Dry Blotting System (Life 
Technology) and then immunoblotted with the following antibodies: CD63 and CD9 (Santa Cruz 
Biotechnology) and hepatocyte growth factor (HGF) (Thermo Fisher Scientific). The protein bands 
were visualized using a ChemiDoc™ XRS + (BioRad) with an enhanced chemiluminescence 
detection kit (ECL) (GE healthcare, Amersham). 
In order to further analyse the protein content of the different EV populations, 100 µg of EV protein 
was hybridized on glass slides from the Human Cytokine Array kit (Ray Biotech) according to the 
manufacturer’s protocol. The kit allows detecting the expression of 80 different cytokines and 
growth factors. 
Electron microscopy. 
Transmission electron microscopy was performed by loading EVs onto 200 mesh nickel formvar 
carbon coated grids (Electron Microscopy Science) for 20 minutes. EVs were then fixed with a 
solution containing 2.5 % glutaraldehyde and 2% sucrose followed by repeated washings in distilled 
water. The samples were than negatively stained with NanoVan (Nanoprobes, Yaphank) and 
examined by Jeol JEM 1010 electron microscope. 
In vitro experiments on mTECs  
For proliferation experiments, mTECs were seeded in 96-well plates at 1,500 cells/well in either: 
100 µl/well of DMEM with 10% FCS (positive control), or 0% FCS (negative control), or 0% FCS 
in the presence of different concentrations of EVs (0.5x107 and 1x107 EVs/ml). DNA synthesis was 
detected through the incorporation of 5-bromo-2’-deoxy-uridine (BrdU) into the cellular DNA after 
48 hours of culture with EVs as per manufacturer’s protocol (Roche Applied Science). 
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SCID mouse model of AKI 
Animal studies were conducted in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals. All procedures were approved by the Ethics Committee of the 
University of Turin and the Italian Health Ministry (authorization number: 211/2016-PR). 
AKI was induced by an intramuscular (i.m) injection of glycerol (Sigma) in SCID mice as described 
previously (17). Glycerol induces myolysis and hemolysis thereby exposing the kidneys to large 
toxic amounts of myoglobin and hemoglobin (29). Briefly, mice were anesthetized with an i.m. 
injection of zolazepam (80 mg/Kg) and xilazina (16 mg/Kg) and then injected with 8 ml/kg of 50% 
glycerol in water. Half the dose was injected into each muscle of the inferior hind limbs. Three days 
after glycerol injection, the mice were treated intravenously with either 120 µl of the vehicle alone 
(n=10) or containing 165x106 particle of the different populations of EVs (n =10 for each 
populations). The mice were sacrificed 5 days after glycerol injection (2 days after EV treatment).  
Blood samples were collected 5 days after glycerol-induced AKI for the measurement of blood urea 
nitrogen (BUN) and creatinine. BUN was measured by direct quantification of serum urea with a 
colorimetric assay kit according to the manufacturer’s protocol (Arbor Assays). Serum creatinine 
was measured using a colorimetric microplate assay based on the kinetic Jaffe reaction as per 
manufacturer’s protocol (Quantichrom Creatinine Assay, BioAssay Systems). 
Renal morphology was evaluated through formalin fixed parafilm embedded tissue staining. 
Briefly, 5 μm-thick paraffin kidney sections were routinely stained with hematoxylin and eosin 
(H&E, Merck) for microscopic evaluation. Luminal hyaline casts and cell necrosis (denudation of 
tubular basement membrane) were assessed in non-overlapping fields (10 for each section) using a 
40x objective (high power filed, HPF). The number of casts and tubular profiles showing necrosis 
were recorded in a single-blind fashion, as described previously (16, 17).  
Immunohistochemistry for the detection of proliferating tubular cells was performed as described 
previously (16, 17). Briefly, paraffin kidney sections were subjected to antigen retrieval, followed 
by blocking and labelling with 1:400 of anti-PCNA (Santa Cruz Biotechnology) and 1:200 of anti-
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BrdU (Dakocytomation). Immunoperoxidase staining was then performed using a 1:300 dilution of 
secondary HRP antibody (Pierce). Scoring for PCNA and BrdU-positive cells was carried out by 
counting the number of positive nuclei per HPF (40x) in 10 randomly chosen sections of the kidney 
cortex.  
Statistical analyses 
Data were analyzed using the GraphPad Prism 6.0 program. Statistical analysis was performed by 
employing either: student’s t-tests, analysis of variance (ANOVA) with Newmann–Keuls’ or 
ANOVA with Dunnet’s multi-comparison tests as deemed appropriate. A p-value of <0.05 was 
considered significant.  
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Results 
Characterization of different populations of MSC-EVs 
Different EV populations were analyzed by NTA to determine their size. The 100K-EVs appeared 
to be homogenous with a mean size of 160+72 nm (Figure 1B). On the other hand, the 10K-EVs 
were more heterogeneous in size containing EVs which on average were much larger (215+110 nm) 
(Figure 1B). Variability in size of the EVs that were fixed as seen by transmission electron 
microscopy was observed, whereby they were smaller than that observed with the NanoSight. This 
could be due to the influence of both temperature and Brownian motion incorporated in the 
nanosight method of EV characterization. In addition, transmission electron microscopy showed the 
presence of bigger EVs in the 10K fraction compared to the 100K fraction (Figure 1C).  
The expression of typical exosomal markers was evaluated in the different EV-populations by 
Western blot analyses. CD63, a fairly common marker for EVs was expressed at low levels in the 
10K-EV population compared to the 100K-EVs (Figure 1D). Furthermore, a similar pattern was 
also observed for the CD9 marker (Figure 1D). FACS analyses showed the presence of several 
markers characteristic of MSCs, such as CD29, CD44, CD73 and CD105, in all the EV populations 
tested (not shown), as described previously for 100KTOT-EVs (17, 25). 
In vivo effects of different populations of MSC-EVs in experimental AKI 
Analyses of renal function indicated that the 100KTOT-EVs significantly improved renal function 
by reducing BUN and creatinine levels compared to AKI mice treated with the vehicle alone (Table 
2). Furthermore, mice treated with the 100K-EVs also improved renal function in a similar fashion 
to the 100KTOT-EV fraction. However, no significant improvement in renal function was observed 
in mice treated with the 10K-EV fraction (Table 2). This was further confirmed by histological 
analyses, whereby, the 10K-EV treatment did not induce a significant recovery in renal histology as 
the formation of hyaline cast and necrotic renal tubules was comparable to AKI mice without EV 
treatment (Figure 2). On the other hand, the 100K-EVs significantly reduced morphological injuries 
in a similar manner to the 100KTOT-EVs (Figure 2). Moreover, both 100K-EVs and 100KTOT-
13 
 
EVs significantly enhanced tubular cell proliferation, compared to the treatment with the vehicle 
alone or with 10K-EVs (Figure 3A). Furthermore, this proliferative effect of 100K-EVs and 
100KTOT-EVs was also observed in vitro on mTECs (Figure 3B). In contrast, the 10K-EVs were 
unable to trigger proliferation of mTECs in vitro (Figure 3B). 
Analyses of EV content: RNAs 
The differential expression of cell cycle specific mRNAs by different EVs was evaluated 
(Supplementary Table 1). The 100K-EVs fraction significantly expressed mRNAs involved in cell 
cycle progression such as CCNB1, CDK8 and CDC6. Conversely, the 10K-EVs, significantly 
expressed only TP53 which is a negative regulator of the cell cycle. Gene expression was further 
confirmed by qRT- PCR (Figure 4). 
Bioanalyzer profiling revealed an enrichment of small RNAs in both the 10K and 100K-EVs 
(Figure 5A). This was followed by comparative miRNA sequencing analysis which was performed 
on different EV populations as follows: (i) 10K vs 100KTOT-EVs, (ii) 100K vs 100KTOT-EVs and 
(iii) 10K vs 100K-EVs. By using a cut-off of RPM ≥ 100 to define the expressed vs not expressed 
miRNAs, we found 160 miRNAs to be present in the 10K-EV population and 164 in the 100K-EVs 
(Supplementary Table 2). On comparing with the 100KTOT-EVs, the two EV populations shared 
124 common miRNAs (Figure 5B). Moreover, we identified 32 miRNAs that were up-regulated 
(FC≥ 1) in the 10K-EV fraction with respect to the 100K-EVs (Table 3). On the other hand, 37 
miRNAs were up-regulated in the 100K-EVs (FC≤ -1) (Table 4).  
Predictive target analysis using Funrich analysis tool conducted on the up-regulated miRNAs in one 
fraction with respect to the other revealed a group of 2,228 selective target genes for the 100K-EVs 
and 1,744 for the 10K-EVs. The biological processes over-represented by the 100K-EV predictive 
genes were mainly associated with protein transport, vitamin metabolism, nucleic acid metabolism, 
cytoskeleton organization, DNA repair, cell differentiation and cell growth (Figure 5C). Selective 
processes represented by the 10K-EV predictive genes were: transport, cell-to-cell communication, 
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apoptosis, fatty acid metabolism, cell growth and cell cycle regulation and matrix adhesion (not 
shown).  
A network analysis of the 100K-EV predictive genes was performed to define their associated 
pathways. What was observed was a high representation of proliferative/anti-apoptotic pathways, 
such as PI3K and mTOR associated signaling events. A robust representation of protein nodes 
clustered around growth factor pathways such as: proteoglycan-syndecan signaling events, 
hepatocyte growth factor (HGF) and insulin-like growth factor 1 (IGF-1) mediated pathway and 
signaling were over-represented in the interactome network created (p<0.001) (Figure 5D). 
Furthermore, signaling associated with cytoskeleton remodeling such as Arf6, integrins and focal 
adhesion kinase were also highly represented, together with angiogenic processes such as of 
PDGFRβ and EGFR signaling events. The same analysis conducted on the 10K predictive genes 
showed a high representation of cell cycle associated pathways such as G1/S transition, S phase and 
cell cycle checkpoint (not shown). 
Analyses of EV content: Protein  
Pro-proliferative effects of EVs could also depend on their protein content such as specific growth 
factors. For this reason, we analyzed the protein content of the different EV populations by an 
antibody array that can evaluate the presence of 80 different cytokines and growth factors semi-
quantitatively. This analysis revealed the presence of 13 cytokines in both the EV-populations 
(Table 5). Growth factors involved in the regulation of biological processes such as hematopoiesis, 
osteocyte differentiation and neuronal development, were differentially expressed in the 10K and 
100K-EVs. The 10K-EVs were positive for several cytokines and chemokines involved in the 
control and regulation of inflammation and immuno-modulation such as IFN-γ and TGF-β. The 
100K-EVs were enriched with HGF (Figure 4C) and IGF-1, two growth factors known to be 
involved in renal regeneration mediated by MSCs. Furthermore, qRT-PCR also confirmed an 
enrichment of HGF mRNA in the 100K-EVs with respect to the 10K-EVs (Figure 4B). No 
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significant difference however, was observed in the mRNA levels of IGF-1 between the 10K and 
100K-EVs (Figure 4B).  
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Discussion 
Human bone marrow MSC-EVs are able to promote regeneration in different animal models of AKI 
and mimic the efficacy of MSCs (16-19, 30, 31). EVs isolated from cultured bone marrow MSCs 
contain vesicles of different size and density. Thus, it was unclear which population of the EVs was 
responsible for the pro-regenerative effect of MSC-EVs observed in AKI mice models. Through 
this study, we have demonstrated that different EV populations can exhibit diverse regenerative 
capabilities on AKI. The 100K population, positive for typical exosomal markers (CD63 and CD9), 
markedly improved both renal function and morphology in the presented AKI model. In contrast, 
the 10K-EVs which were enriched in microvesicles expressing only the MSC markers, did not have 
any significant effect on renal function and morphology. These results therefore suggest that the 
pro-regenerative effect of MSC-EVs observed is mainly ascribed to exosomes. However, as the 
total EV population has the same effect as the exosomal fraction, it can be speculated that 
microvesicles do not interfere in a negative manner. 
Several studies have reported different biological properties of exosomes and microvesicles. For 
instance, exosomes obtained from murine MSCs were able to not only prevent but also reverse 
monocrotaline-induced pulmonary hypertension, whereas the MVs were ineffective (15). Another 
study showed that exosomes and microvesicles derived from endothelial colony forming cells had 
different regenerative properties when injected in an experimental murine model of AKI induced by 
ischemia reperfusion injury (IRI). Exosomes showed pro-regenerative effects in IRI-mice, whereas 
microvesicles were ineffective (32). In addition, exosomes and microvesicles derived from human 
colon cancer cells exhibited distinct biological activities; in particular, exosomes which promoted 
greater invasion compared to microvesicles (33). EVs derived from murine and/or human BM-
MSCs reversed the radiation damage to marrow hematopoietic cells both in vitro and in vivo. In this 
case, preparations containing both exosomes and microvesicles were more effective as oppose to 
either microvesicles or exosomes alone (34). 
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In this study, we observed that the exosome-enriched 100K-EVs, but not the 10K-EVs, exerted a 
pro-proliferative effect on murine tubular cells, both in vitro and in vivo. The differential biological 
activity of different vesicle populations has been ascribed to their distinct molecular content. In the 
100K-EVs, we found the presence of CCNB1, CDK8 and CDC6 transcripts. CCNB1 mRNA, 
encodes for the protein named G2/mitotic-specific cyclin-B1 (35). Cyclin B1 is involved in the 
early events of mitosis, such as chromosome condensation, nuclear envelope breakdown, and 
spindle pole assembly. Once activated, cyclin B1 promotes several events involved in the early 
stages of mitosis. CDK8 encodes for a protein member of the cyclin-dependent protein kinase 
(CDK) family that influences binding of RNA polymerase II to the mediator complex (36). CDC6, 
or cell division cycle 6, encodes for a protein that is an essential regulator of DNA replication and 
also plays an important role in the activation and maintenance of checkpoint mechanisms in the cell 
cycle that co-ordinates S phase and mitosis (37). 
In the 10K-EVs, we detected only the presence of TP53 that is a well-known negative regulator of 
the cell cycle (38), thus explaining the absence of a pro-proliferative effect. It has been previously 
shown that miRNAs shuttled by EVs, derived from different stem cell types, influence EV-pro-
regenerative effect in different AKI-models (18, 39, 40). In addition, the miRNA content in the 
exosome and microvesicle enriched fractions in this study was distinct. Bio-informatic analyses 
indicated that miRNA present in the 100K-EVs might account for regulation of proliferative/anti-
apoptotic pathways. Signaling associated with cytoskeleton remodeling and angiogenic processes 
were also highly represented in this fraction. A robust representation of protein nodes clustered 
around growth factor pathways, in particular signaling mediated by IGF-1 and HGF were highly 
represented in the 100K-EVs interactome network. Moreover, some miRNAs particularly enriched 
in 100K-EVs are known to be involved in renal regeneration. For instance, miR-486-5p has been 
implicated in reparative process induced by exosomes, derived from endothelial colony forming 
cells, in IRI (40). Likewise, miR-126 has also been associated with kidney regeneration induced by 
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EPC-derived EVs in an IRI model of kidney injury (39). Moreover, miR-34a induced via p53 in 
cisplatin nephrotoxic AKI, has been shown to protect tubular cells from injury and death (41). 
The pro-proliferative effects of 100K-EVs could also be partly attributed to their content in specific 
growth factors. We found that growth factors involved in different biological processes such as the 
control of hematopoiesis, neuronal development and osteocyte differentiation were differentially 
distributed in the 10K and 100K-EVs. The 10K-EVs shuttled cytokines involved in the control and 
regulation of inflammation as well as immuno-modulation, and chemokines/chemokines receptors 
known to be expressed by MSCs and to be involved in the MSC recruitment (42). Nonetheless, they 
contained less pro-proliferative growth factors compared to the 100K-EVs. The latter on the other 
hand was particularly enriched in growth factors known to be involved in renal regeneration such as 
IGF-1 and HGF. For instance, Imberti et al has reported that MSCs exert beneficial effects on 
tubular cell repair by producing the mitogenic and pro-survival factor IGF-1 in an AKI model 
induced by cisplatin (43). The horizontal transfer of IGF-1 receptor mRNA to tubular cells through 
MSC-derived exosomes potentiates tubular cell sensitivity to locally produced IGF-1 providing a 
support for renal repair post AKI (44). We also found that 100K EVs were enriched in both HGF 
protein and mRNA. Further to this, it has been shown previously that HGF mRNA present in EVs 
derived from both human Wharton jelly-derived MSCs and rat BM-MSCs, was delivered to tubular 
cells and then translated into protein (45, 46). Transfer of HGF to resident cells has been shown to 
promote renal repair preventing fibrogenesis in models of IRI (45, 46). 
In conclusion, this study demonstrated that despite their heterogeneity EVs derived from MSCs are 
able to promote AKI recovery. This biological effect has been ascribed to the ability of EVs to 
induce tubular cell proliferation leading to the repopulation of injured tubules. The EV fraction 
enriched in exosomes contained mRNAs, miRNAs and growth factors that may act synergistically 
to induce the pro-proliferative effects observed and may explain the ability of this fraction to 
promote AKI recovery. In contrast, the 10K population, which was not effective, displayed a 
molecular composition that was low in the expression of pro-proliferative factors. Since 100KTOT-
19 
 
EVs and 100K-EVs did not significantly differ in terms of functional, morphological and 
proliferative effects, we can speculate that the 10K EV population did not interfere with the 
regenerative capacity of the exosomal population in AKI. This observation may be relevant for a 
future clinical application of EVs, which would require the set up in GMP conditions with minimal 
manipulation and loss/damage of EVs. Our data indicated that it is not necessary to remove 
microvesicles from MSC-EV preparation to obtain a regenerative effect. 
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